VINC Company Profile and Key Details

VINC has shown weak momentum, losing -1.02% over the past week and -96.09% over the past quarter, though year-to-date performance is down -99.08%. Short-term trend indicators are bullishly aligned (SMA20 -5.26%, SMA50 -81.97%, SMA200 -99.08%). The stock’s 14-day RSI is 24.64 (weak momentum), while the ATR of 0.03 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -99.72% below its high and over 15.59% above its low. Average 10-day trading volume of 19.43 thousand shares is significantly above the 3-month average of 5.96 thousand, indicating heightened recent market interest.

The latest quarter delivered EPS of -$4.20. The next quarter is forecast at $nan. Next year's EPS is expected at $50.49. Vincerx Pharma, Inc. earnings surprise history is a mixed track record. The quarter that ended March 27, 2025, missed forecasts by 23.53%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include -45.24% in March 29, 2024.

Vincerx Pharma, Inc. has 5.23 million shares outstanding. The public float is 4.67 million shares, elevated short interest at 2.72% of float. This equals 137.20 thousand shares. The short ratio is 0.1 days. Institutional investors hold 5.48% of the float. Insiders own 4.11%. Hwang Sooin holds 390.49 thousand shares, THOMAS TOM C has 219.94 thousand shares and Hamdy Ahmed MD has 96.06 thousand shares.

Vincerx Pharma, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.48. This means the shares are trading below this model’s fair value.

The stock is currently mid-range between its 52-week high and low $0.00 and $1.43. With a market capitalization of about $66.47 thousand, Vincerx Pharma, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.44). Key stats such as the average daily volume over the past year has been around 5.08 thousand shares, volume is running light vs its 52-week average. Headquartered in Palo Alto, CA, Vincerx Pharma, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Raquel E. Izumi, the company employs approximately 13 people and listed since May 27, 2020. Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering and advancing innovative treatments for cancer, specifically addressing areas of high medical need within the U.S.

Vincerx Pharma, Inc. (NASDAQ:VINC) shares are down -99.08% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Vincerx Pharma, Inc. trading at a premium to the broader market with a P/E of -0.0. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $17.50, suggesting 137695.28% upside. Our AI forecast model points to short-term weakness (-21.26% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Vincerx Pharma, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -21.26%, with price expected at $0.01 by August 17, 2026, within a range of $0.01 to $0.01 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by October 30, 2026, with a range of $0.00 to $0.16. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by August 03, 2027, within a range of $0.00 to $1.32.

Vincerx Pharma, Inc. trades at a P/E ratio of -0.0, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.02 suggesting the stock is closer to book value. The P/FCF stands at -0.0, also above market averages.